Written and maintained by CASRAI Editorial Board
Published
On this page
Telehealth informed consent (also termed informed consent telemedicine) is the clinical and legal process of educating a patient about the specific operational scope, diagnostic limitations, electronic privacy risks, emergency escalation protocols, and financial responsibilities of receiving healthcare via synchronous audio-video, audio-only, or asynchronous store-and-forward technology, and documenting the patient’s voluntary agreement prior to initiating virtual care.
Unlike a general HIPAA Notice of Privacy Practices acknowledgement (see HIPAA authorization vs informed consent), telehealth informed consent is governed by state medical practice acts, state Medicaid agency reimbursement rules, and clinical practice standards issued by the Agency for Healthcare Research and Quality (AHRQ) and the Federation of State Medical Boards (FSMB).
What Is Telehealth Informed Consent?
To understand what is telehealth informed consent from a clinical risk management perspective, organizations must distinguish between standard medical treatment consent and the modality-specific risks introduced by remote care. According to AHRQ’s guidance on obtaining informed consent for telehealth and FSMB’s telemedicine policy framework, a legally and clinically defensible telehealth consent instrument must disclose seven core elements:
- Nature and Modality of the Telemedicine Encounter: A plain-language explanation of whether the service uses real-time interactive audio-video, audio-only telephone, asynchronous store-and-forward image/data transmission, or remote patient monitoring (RPM).
- Diagnostic Limitations of Virtual Examination: An explicit disclosure that the clinician cannot perform hands-on physical palpation, auscultation (unless peripheral hardware is present), or immediate point-of-care testing, and that technical failures or clinical ambiguity may require converting the encounter to an in-person office or emergency department visit.
- Originating Site Location & Emergency Escalation Protocol: Confirmation that the patient must disclose their exact physical address and telephone number at the start of every virtual visit (see originating site telehealth) so the clinician can dispatch local emergency medical services (EMS) if a medical or behavioral health crisis occurs and verify state licensure jurisdiction.
- Electronic Security and Privacy Risks: Disclosure that although the telehealth platform uses HIPAA-compliant encryption (such as WebRTC DTLS-SRTP), electronic transmissions carry residual cybersecurity risks, and patients are responsible for ensuring privacy in their physical environment.
- Third-Party Observers, Trainees, and Family Members: Rules requiring both the clinician and the patient to disclose all individuals present in the room at the distant and originating sites, and requiring patient permission before medical students, residents, or interpreters join the virtual session.
- Right to Withdraw or Refuse Telehealth: Assurance that the patient may withhold or withdraw consent to telehealth at any time without losing the right to future care or treatment.
- Billing, Co-Payments, and Out-of-Network Disclosures: Explanation of insurance coverage, patient cost-sharing, and applicable self-pay rates before the session begins.
Comparison of Telehealth Consent Modalities Across Care Settings
| Consent Modality | Primary Clinical Use Case | Verification & Audit Trail Mechanism | Regulatory & Payer Considerations |
|---|---|---|---|
| Pre-Visit Electronic Signature (eConsent) | Scheduled ambulatory video visits and longitudinal specialty clinics | Timestamped electronic signature, IP address, and PDF/FHIR `Consent` archive during digital intake | Satisfies all state written and verbal consent statutes; preferred for audit readiness |
| Documented Verbal Consent at Visit Start | Urgent care telemedicine, audio-only visits, or patients unable to complete pre-visit forms | Clinician reads standardized script on call and selects structured EHR smart-phrase attestation | Permitted by most state medical boards and Medicare CCM/RPM rules when documented in the chart |
| Multi-Part AI & Recording Consent | Telehealth visits utilizing ambient AI medical scribes or session video recording | Explicit opt-in checkbox or recorded verbal consent covering voice capture and AI processing | Required under two-party (all-party) state wiretapping laws and institutional AI governance |
How Is Telehealth Informed Consent Used in Clinical Research and Healthcare?
Examining how is telehealth informed consent used in clinical research and healthcare highlights how modern health systems embed consent directly into automated pre-visit workflows and decentralized clinical trials:
1. Integration into Automated Patient Intake and Telemedicine Workflows
In high-volume ambulatory clinics, collecting verbal consent during the first three minutes of every 15-minute video appointment erodes clinician time. Consequently, health systems embed telehealth informed consent directly into the pre-visit digital patient intake and patient intake process:
- Automated Pre-Visit Triggering: When an appointment is booked with a telehealth place-of-service code (POS 02 or POS 10), the automated patient intake engine checks whether the patient has an active, non-expired telehealth consent on file (typically valid for 12 months under institutional policy, unless state law requires per-encounter attestation).
- Telehealth Workflow Gating: Before entering the virtual waiting room, the patient completes identity verification, confirms their current physical state/address for licensure routing, signs the electronic telehealth consent form, and completes clinical screening questionnaires on their smartphone or browser.
2. Informed Consent for Artificial Intelligence in Telemedicine
A rapidly expanding regulatory requirement is informed consent artificial intelligence within the telehealth workflow and telemedicine workflow. When clinicians deploy ambient AI medical scribes, real-time transcription, or generative clinical decision support during a virtual visit, general telehealth consent is frequently insufficient on its own:
- All-Party Wiretapping & Biometric Laws: In all-party (two-party) recording consent jurisdictions (such as California, Florida, Illinois, Massachusetts, Pennsylvania, and Washington), recording or streaming patient-clinician conversation to a third-party cloud speech processor without explicit consent violates state wiretapping statutes. Organizations therefore pair general telehealth consent with a dedicated AI scribe consent form clause disclosing that an AI tool is transcribing the visit to draft clinical notes and that a licensed clinician reviews and edits the final record.
- State AI Healthcare Disclosure Mandates: Recent state legislation (such as California AB 3030 and Texas / Utah AI disclosure frameworks) establishes transparency requirements when generative AI is used to communicate clinical information to patients, reinforcing the practice of including explicit AI disclosure language in patient intake packets.
3. HL7 FHIR `Consent` Resource and Decentralized Clinical Trials (DCTs)
In health informatics and decentralized clinical trials (governed by FDA Electronic Informed Consent guidance under 21 CFR Parts 11 and 50 and ICH E6(R3) Annex 2), telehealth consent is stored and exchanged using the HL7 FHIR R4 `Consent` resource:
- `Consent.scope` & `Consent.category`: Coded to distinguish clinical treatment teleconsent (`treatment`), research participation (`research`), and privacy disclosures (`patient-privacy`).
- `Consent.sourceAttachment` / `Consent.sourceReference`: Links the structured FHIR resource to the signed PDF artifact (`DocumentReference`) or completed `QuestionnaireResponse` captured during digital patient intake.
- `Consent.provision`: Encodes granular opt-in/opt-out permissions (such as permitting telehealth treatment while declining session recording or secondary AI model training).
Frequently Asked Questions
What is telehealth informed consent?
Telehealth informed consent is the process of informing a patient about how telemedicine works, the diagnostic limitations of a remote exam compared to an in-person visit, electronic privacy and security risks, emergency location protocols, and billing policies, and recording the patient’s agreement before delivering virtual care.
How is telehealth informed consent used in clinical research and healthcare?
In healthcare, telehealth informed consent is integrated into automated digital patient intake workflows—or documented verbally at the start of a virtual visit—to satisfy state medical board, Medicaid, and malpractice risk requirements, as well as to obtain permission for ambient AI medical scribes. In clinical research, electronic informed consent (eConsent) conducted via telehealth allows investigators to enroll and consent remote trial participants under FDA 21 CFR Part 11/50 and ICH E6(R3) decentralized trial guidelines.







